Kaufman Rossin Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kaufman Rossin Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-749	Closed	-$298K	–	105
2025 Q4	$298K	Buy	749 +266	+55%	+$118K	0.16%	104
2025 Q3	$220K	Buy	+483	New	+$197K	0.12%	138
2025 Q2	–	Sell	-1,300	Closed	-$351K	–	142
2025 Q1	$351K	Buy	+1,300	New	+$334K	0.25%	71

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kaufman Rossin Wealth's ALNY Position: Q1 2026 in Review

Kaufman Rossin Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 749 shares — an estimated $298K sold.

Kaufman Rossin Wealth first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $351K in Q1 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Kaufman Rossin Wealth reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Kaufman Rossin Wealth sold 749 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $298K.
Kaufman Rossin Wealth first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Kaufman Rossin Wealth's Alnylam Pharmaceuticals position peaked at $351K in Q1 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Kaufman Rossin Wealth's 13F filing for Q1 2026, filed 17 Apr 2026.